PIM447 + Ruxolitinib + LEE011
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelofibrosis
Conditions
Myelofibrosis
Trial Timeline
May 21, 2015 → Nov 9, 2020
NCT ID
NCT02370706About PIM447 + Ruxolitinib + LEE011
PIM447 + Ruxolitinib + LEE011 is a phase 1 stage product being developed by Novartis for Myelofibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02370706. Target conditions include Myelofibrosis.
What happened to similar drugs?
2 of 19 similar drugs in Myelofibrosis were approved
Approved (2) Terminated (3) Active (14)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02370706 | Phase 1 | Completed |
Competing Products
20 competing products in Myelofibrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 36 |
| Nusivertib + Ruxolitinib + Momelotinib | Sumitomo Pharma | Phase 1/2 | 39 |
| Ruxolitinib + Navitoclax | AbbVie | Phase 2 | 35 |
| ABBV-744 + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Placebo for Navitoclax + Ruxolitinib + Navitoclax | AbbVie | Phase 3 | 40 |
| Mivebresib + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 21 |
| Navitoclax + Venetoclax | AbbVie | Pre-clinical | 26 |
| Navitoclax + Ruxolitinib + Best Available Therapy (BAT) | AbbVie | Phase 3 | 44 |
| NS-018 + Best Available Therapy | Nippon Shinyaku | Phase 2 | 27 |
| AZD1480 | AstraZeneca | Phase 1 | 29 |
| Bomedemstat | Merck | Phase 2 | 31 |
| Peginterferon alfa-2a | Merck | Phase 2 | 27 |
| Bomedemstat | Merck | Phase 1/2 | 32 |
| MBG453 + NIS793 + Spartalizumab + Decitabine | Novartis | Phase 1 | 21 |
| LDE225 + INC424 | Novartis | Phase 1/2 | 32 |
| Imatinib mesylate | Novartis | Phase 2 | 35 |
| Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793 | Novartis | Phase 1/2 | 24 |
| Ruxolitinib + Ruxolitinib Placebo | Novartis | Phase 3 | 32 |
| Ruxolitinib | Novartis | Pre-clinical | 30 |
| ruxolitinib | Novartis | Phase 2 | 35 |